Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 292-697-5
CAS number: 90989-41-6
Benzene is readily absorbed following inhalation or oral exposure. Although it is also readily absorbed from the skin, a significant amount evaporates from the skin
surface. Absorbed benzene is rapidly distributed throughout the body and tends to partition into fatty tissues. The liver serves an important function in benzene metabolism.
toxicokinetics of benzene has been extensively studied and was recently
reviewed by ATSDR (Toxicological profile for benzene, ATSDR, 2007).
ATSDR concluded "Inhalation exposure is probably the major route of
human exposure to benzene, although oral and dermal exposures are also
important. Benzene is readily absorbed following inhalation or oral
exposure. Although benzene is also readily absorbed from the skin, a
significant amount of a dermal application evaporates from the skin
surface. Absorbed benzene is rapidly distributed throughout the body and
tends to partition into fatty tissues. The liver serves an important
function in benzene metabolism, which results in the production of
several reactive metabolites. Although it is widely accepted that
benzene toxicity is dependent upon metabolism, no single benzene
metabolite has been found to be the major source of benzene
hematopoietic and leukaemogenic effects. At low exposure levels, benzene
is rapidly metabolized and excreted predominantly as conjugated urinary
metabolites. At higher exposure levels, metabolic pathways appear to
become saturated and a large portion of an absorbed dose of benzene is
excreted as parent compound in exhaled air. Benzene metabolism appears
to be qualitatively similar among humans and various laboratory animal
species. However, there are quantitative differences in the relative
amounts of benzene metabolites”. The present analysis confirms the ATSDR
statement. More specifically, human inhalation exposure is estimated to
be approximately 50%, oral exposure assumed to be 100% (this value used
for DN(M)EL calculations). Percutaneous absorption is estimated at 0.1%
(Modjtahedi and Maibach, 2008) whereas a QSAR model determined a maximum
value of 1.5% (Ten Berge, 2009).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Ce site web utilise des cookies afin de vous garantir la meilleure expérience possible sur nos sites web.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again